No Data
No Data
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of ad
Avadel Gains for a Second Day as Analysts See It Prevailing in Case Vs Jazz/FDA
Avadel Pharma Gains During Hearing Over Dispute on FDA Approval of a Sleep Disorder Drug
Jazz Pharmaceuticals(JAZZ.US) Officer Sells US$548.25K in Common Stock
$Jazz Pharmaceuticals(JAZZ.US)$ Officer Patil Neena M sold 5,000 shares of common stock on May 3, 2024 at an average price of $109.65 for a total value of $548.25K.Source: Announcement What is stateme